Hutchmed (HCM) said late Tuesday a phase III registration part of a clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China met its primary endpoint.
The study showed a durable hemoglobin response rate within weeks five to 24 of treatment, the company said.
Autoimmune hemolytic anemia is an autoimmune disorder characterized by the destruction of red blood cells.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.